JP2024170466A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024170466A5 JP2024170466A5 JP2024147372A JP2024147372A JP2024170466A5 JP 2024170466 A5 JP2024170466 A5 JP 2024170466A5 JP 2024147372 A JP2024147372 A JP 2024147372A JP 2024147372 A JP2024147372 A JP 2024147372A JP 2024170466 A5 JP2024170466 A5 JP 2024170466A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- use according
- inhibitor
- additional anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025154024A JP2025178337A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
| JP2025154025A JP2025178338A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062957758P | 2020-01-06 | 2020-01-06 | |
| US62/957,758 | 2020-01-06 | ||
| US202062985152P | 2020-03-04 | 2020-03-04 | |
| US62/985,152 | 2020-03-04 | ||
| US202063198803P | 2020-11-13 | 2020-11-13 | |
| US63/198,803 | 2020-11-13 | ||
| PCT/US2021/012329 WO2021142002A1 (en) | 2020-01-06 | 2021-01-06 | Anti-ccr8 antibodies and uses thereof |
| JP2022535120A JP7606518B2 (ja) | 2020-01-06 | 2021-01-06 | 抗ｃｃｒ８抗体及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535120A Division JP7606518B2 (ja) | 2020-01-06 | 2021-01-06 | 抗ｃｃｒ８抗体及びその使用 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025154024A Division JP2025178337A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
| JP2025154025A Division JP2025178338A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024170466A JP2024170466A (ja) | 2024-12-10 |
| JP2024170466A5 true JP2024170466A5 (https=) | 2025-02-12 |
| JP7793001B2 JP7793001B2 (ja) | 2025-12-26 |
Family
ID=74418541
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535120A Active JP7606518B2 (ja) | 2020-01-06 | 2021-01-06 | 抗ｃｃｒ８抗体及びその使用 |
| JP2024147372A Active JP7793001B2 (ja) | 2020-01-06 | 2024-08-29 | 抗ｃｃｒ８抗体及びその使用 |
| JP2025154024A Pending JP2025178337A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
| JP2025154025A Pending JP2025178338A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535120A Active JP7606518B2 (ja) | 2020-01-06 | 2021-01-06 | 抗ｃｃｒ８抗体及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025154024A Pending JP2025178337A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
| JP2025154025A Pending JP2025178338A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11859000B2 (https=) |
| EP (1) | EP4087607A1 (https=) |
| JP (4) | JP7606518B2 (https=) |
| KR (2) | KR20250095745A (https=) |
| CN (1) | CN114929278A (https=) |
| AR (1) | AR132614A2 (https=) |
| AU (2) | AU2021205877B2 (https=) |
| CA (1) | CA3160204A1 (https=) |
| IL (2) | IL321341A (https=) |
| MX (3) | MX2022008341A (https=) |
| TW (2) | TWI906906B (https=) |
| WO (1) | WO2021142002A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3616720B1 (en) * | 2017-03-29 | 2021-02-17 | Shionogi&Co., Ltd. | Pharmaceutical composition for cancer treatment |
| KR20250095745A (ko) | 2020-01-06 | 2025-06-26 | 백시넥스 인코포레이티드 | 항-ccr8 항체 및 이의 용도 |
| WO2021155097A1 (en) * | 2020-01-29 | 2021-08-05 | The Wistar Institute Of Anatomy And Biology | Cd40-l blockade to enhance synthetic antibody therapy |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| CN115052892B (zh) | 2020-10-16 | 2023-07-07 | 礼新医药科技(上海)有限公司 | 抗ccr8单克隆抗体及其用途 |
| CN117295820A (zh) | 2021-03-31 | 2023-12-26 | 盐野义制药株式会社 | 以ccr8作为抗原识别的嵌合抗原受体 |
| BR112023025433A2 (pt) | 2021-06-04 | 2024-02-27 | Amgen Inc | Anticorpos anti-ccr8 e seus usos |
| EP4491635A3 (en) * | 2021-07-27 | 2025-04-02 | AbbVie Inc. | Anti-ccr8 antibodies |
| WO2023020621A1 (en) * | 2021-08-20 | 2023-02-23 | Hifibio (Hk) Limited | Anti-ccr8 antibodies and uses thereof |
| CN119930823A (zh) * | 2021-12-23 | 2025-05-06 | 乐普创一生物科技（上海）有限公司 | 抗ccr8抗体及其应用 |
| US20230279130A1 (en) * | 2022-01-14 | 2023-09-07 | Qilu Puget Sound Biotherapeutics Corporation | Anti-ccr8 antibodies |
| CN116789820A (zh) * | 2022-03-18 | 2023-09-22 | 北京天诺健成医药科技有限公司 | 一种新型免疫调节剂的开发和应用 |
| WO2023206350A1 (en) * | 2022-04-29 | 2023-11-02 | Analytical Biosciences Shanghai Limited | Anti-ccr8 antibodies and uses thereof |
| US20260028409A1 (en) | 2022-05-24 | 2026-01-29 | Bristol-Myers Squibb Company | Antibodies that bind to human ccr8 |
| EP4536278A2 (en) | 2022-06-07 | 2025-04-16 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
| US20250388684A1 (en) * | 2022-07-07 | 2025-12-25 | Sichuan Swiftbio Biotechnology Co., Ltd | Anti-ccr8 antibody and use thereofr |
| CA3263543A1 (en) * | 2022-08-04 | 2024-02-08 | Beone Medicines I Gmbh | CCR8 ANTIBODIES AND METHODS OF USE |
| KR20250052418A (ko) * | 2022-08-19 | 2025-04-18 | 피브로겐, 인크. | 항-ccr8 항체 및 그의 용도 |
| WO2024062072A2 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062082A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062076A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062019A1 (en) | 2022-09-21 | 2024-03-28 | Synabs | Anti-ccr8 antibodies and uses thereof |
| EP4613766A1 (en) * | 2022-11-04 | 2025-09-10 | Biotheus Inc. | Anti-ccr8 antibody and use thereof |
| CN120239710A (zh) * | 2022-11-22 | 2025-07-01 | 上海宏成药业有限公司 | 抗ccr8抗体及其用途 |
| WO2024120418A1 (zh) * | 2022-12-07 | 2024-06-13 | 广东菲鹏制药股份有限公司 | 抗ccr8抗体及其应用 |
| AR131786A1 (es) | 2023-02-06 | 2025-04-30 | Bayer Ag | Combinación de anticuerpos ccr8 con inhibidores de dgk |
| WO2024240224A1 (zh) * | 2023-05-23 | 2024-11-28 | 再鼎医药(上海)有限公司 | 包含抗ccr8抗体的制剂及其用途 |
| JPWO2024248037A1 (https=) | 2023-05-30 | 2024-12-05 | ||
| EP4725967A1 (en) * | 2023-06-12 | 2026-04-15 | Nanjing Probio Biotech Co., Ltd. | Antibody binding to human ccr8 and the use thereof |
| CN121152808A (zh) * | 2023-06-16 | 2025-12-16 | 嘉和生物药业有限公司 | 抗ccr8抗体和抗ccr8/ctla4双特异性抗体 |
| CN117285627B (zh) * | 2023-09-06 | 2024-06-14 | 百济神州(上海)生物科技有限公司 | 抗ccr8抗体及其用途 |
| EP4590714A1 (en) | 2023-09-21 | 2025-07-30 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| EP4590715A1 (en) | 2023-09-21 | 2025-07-30 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2025076288A1 (en) | 2023-10-06 | 2025-04-10 | Amgen Inc. | Combination therapy for cancer treatment |
| AR134514A1 (es) | 2023-12-01 | 2026-01-21 | Gilead Sciences Inc | Proteína de fusión anti-fap-ligera y uso de esta |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025186043A1 (en) | 2024-03-06 | 2025-09-12 | Bayer Aktiengesellschaft | Pharmaceutical formulation for anti-ccr8 antibodies |
| WO2025191147A1 (en) | 2024-03-14 | 2025-09-18 | Synabs | Anti-ccr8 antibodies and uses thereof |
| WO2025226603A1 (en) | 2024-04-22 | 2025-10-30 | Surface Oncology, LLC | Methods for treating cancer using anti-ccr8 antibodies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20260056209A1 (en) | 2024-06-14 | 2026-02-26 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026017820A1 (en) * | 2024-07-18 | 2026-01-22 | Egle Therapeutics | Fusion protein for cancer treatment |
| EP4681780A1 (en) * | 2024-07-18 | 2026-01-21 | Egle Therapeutics | Immunocytokine for cancer treatment |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
| PT1231268E (pt) | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US6001329A (en) | 1996-05-06 | 1999-12-14 | Uab Research Foundation | Radiolabeled fusion toxins for cancer therapy |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6995259B1 (en) | 1998-10-23 | 2006-02-07 | Sirna Therapeutics, Inc. | Method for the chemical synthesis of oligonucleotides |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| KR20130108481A (ko) | 2005-08-19 | 2013-10-02 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| WO2007044756A2 (en) | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| WO2013131010A2 (en) | 2012-03-02 | 2013-09-06 | Icahn School Of Medicine At Mount Sinai | Function of chemokine receptor ccr8 in melanoma metastasis |
| GB2519786A (en) | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
| BR112016015140A2 (pt) | 2013-12-30 | 2018-01-23 | Epimab Biotherapeutics Inc. | imunoglobulina com fabs in-tandem e usos das mesmas |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
| US10087259B1 (en) * | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| WO2018112033A1 (en) * | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs |
| EP3616720B1 (en) * | 2017-03-29 | 2021-02-17 | Shionogi&Co., Ltd. | Pharmaceutical composition for cancer treatment |
| WO2019157098A1 (en) * | 2018-02-06 | 2019-08-15 | Advaxis, Inc. | Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use |
| KR20250095745A (ko) | 2020-01-06 | 2025-06-26 | 백시넥스 인코포레이티드 | 항-ccr8 항체 및 이의 용도 |
-
2021
- 2021-01-06 KR KR1020257019586A patent/KR20250095745A/ko active Pending
- 2021-01-06 US US17/142,862 patent/US11859000B2/en active Active
- 2021-01-06 IL IL321341A patent/IL321341A/en unknown
- 2021-01-06 AU AU2021205877A patent/AU2021205877B2/en active Active
- 2021-01-06 TW TW113121774A patent/TWI906906B/zh active
- 2021-01-06 JP JP2022535120A patent/JP7606518B2/ja active Active
- 2021-01-06 KR KR1020227020514A patent/KR102821932B1/ko active Active
- 2021-01-06 CA CA3160204A patent/CA3160204A1/en active Pending
- 2021-01-06 IL IL294330A patent/IL294330B2/en unknown
- 2021-01-06 MX MX2022008341A patent/MX2022008341A/es unknown
- 2021-01-06 WO PCT/US2021/012329 patent/WO2021142002A1/en not_active Ceased
- 2021-01-06 CN CN202180007992.9A patent/CN114929278A/zh active Pending
- 2021-01-06 TW TW110100492A patent/TWI845803B/zh active
- 2021-01-06 EP EP21702556.8A patent/EP4087607A1/en active Pending
-
2022
- 2022-07-05 MX MX2024002152A patent/MX2024002152A/es unknown
- 2022-07-05 MX MX2024002158A patent/MX2024002158A/es unknown
-
2023
- 2023-11-17 US US18/512,759 patent/US12496342B2/en active Active
-
2024
- 2024-05-06 AR ARP240101148A patent/AR132614A2/es unknown
- 2024-08-23 AU AU2024216306A patent/AU2024216306A1/en active Pending
- 2024-08-29 JP JP2024147372A patent/JP7793001B2/ja active Active
-
2025
- 2025-09-17 JP JP2025154024A patent/JP2025178337A/ja active Pending
- 2025-09-17 JP JP2025154025A patent/JP2025178338A/ja active Pending
- 2025-11-19 US US19/394,184 patent/US20260091108A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024170466A5 (https=) | ||
| IL321341A (en) | Anti-CCR8 antibodies and their uses | |
| JPWO2021142002A5 (https=) | ||
| JP7608164B2 (ja) | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ | |
| Gan et al. | Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy | |
| CN108601828B (zh) | 包含抗folr1免疫缀合物的治疗组合 | |
| JP7137474B2 (ja) | ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法 | |
| TWI908743B (zh) | 抗dll3藥劑之給藥方案 | |
| JP2018525354A5 (https=) | ||
| TW201834697A (zh) | Her2標靶抗體－藥物結合物之組合療法 | |
| US12234293B2 (en) | Treatment for primary amyloidosis with anti-BCMA binding protein | |
| CN118078987A (zh) | 抗folr1免疫缀合物与抗pd-1抗体的组合 | |
| CN112218662A (zh) | 抗cd37免疫缀合物给药方案 | |
| JP2019023227A (ja) | 神経障害及び疼痛のｅｇｆｒ標的治療 | |
| TW202116810A (zh) | 用於治療癌症之人化抗ｌｉｖ１抗體 | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| EP3691682A1 (en) | Combination treatment for cancer | |
| IL322208A (en) | Methods and preparations for combined therapy | |
| AU2022331610A1 (en) | Interleukin-12 variants and methods of use | |
| TW202306588A (zh) | 抗體-藥物結合物與免疫檢查點抑制劑組合用於治療泌尿上皮癌之用途 | |
| CN110177807B (zh) | 使用抗MUC1抗体和ErbB抑制剂的抗癌治疗 | |
| TW202508637A (zh) | 修飾的抗體、其抗體片段和抗體藥物偶聯物 | |
| KR20250069817A (ko) | Pd-1 또는 pd-l1 억제제 및 클라우딘 18.2를 표적화하는 항체-약물 콘쥬게이트를 사용한 암 치료 | |
| KR102544135B1 (ko) | c-Kit을 표적으로 하는 면역접합체 | |
| Junttila et al. | 515 POSTER Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel |